CommercialCoverageHigh impact
Cryoablation (CPB 0100, reviewed 2026-08-04)
Aetna·Oncology, Cardiology, Urology +9 more·Medical Policy
Effective date
Aug 4, 2026
We identified it
Aug 14, 2026
Summary
Aetna has issued a comprehensive clinical policy bulletin (CPB 0100) establishing medical necessity criteria for cryoablation procedures across multiple anatomical sites and conditions. The policy clearly distinguishes between covered indications (e.g., renal masses up to 4cm, prostate cancer, atrial fibrillation, cervical dysplasia) and experimental/non-covered applications (e.g., breast carcinoma, benign prostatic hypertrophy, osteoarthritis). Billing teams must immediately implement these criteria as authorization rules to ensure claims are processed only when medical necessity requirements are met.
Action Required
Immediately: Billing team must implement Aetna's CPB 0100 cryoablation coverage criteria in the authorization and claims adjudication system. REQUIREMENTS: (1) Configure system to require medical necessity documentation before processing claims for CPT codes 0441T, 20983, 31641, 32994, 33254-33259, 43229-43270, 50250, 50593, 55873, 57511, 64600, 67101-67108, 93657, 0581T, 1040T, and 19105. (2) For covered indications, verify: renal masses ≤4cm with high-risk surgical status/renal insufficiency/solitary kidney; prostate cancer T1-T3 stage; atrial fibrillation drug-resistant/drug-intolerant; pulmonary metastases ≤6 lesions each ≤4cm; bone metastases ≤2cm; adrenal metastases ≤4cm; sacral chordomas <10cm. (3) Flag as non-covered (experimental): breast carcinoma, fibroadenoma, benign prostatic hypertrophy, Barrett's esophagus without dysplasia, osteoarthritis, most soft tissue tumors not listed as covered, and all other unlisted indications. (4) Providers must submit claims with specific size measurements, patient risk stratification, and disease staging. (5) Update encounter templates and prior authorization forms to require documentation of selection criteria. (6) Train billing and authorization staff on covered vs. experimental distinctions. Failure to implement will result in claim denials for non-compliant submissions and potential audit exposure.